Therapeutics Dataset from COVID-19 Medicine Delivery Units in England: an OpenSAFELY Data Report
Authors:
- Linda NabLNLinda Nab
- Amelia GreenAGAmelia Green
- Rose HigginsRHRose Higgins
- Bang ZhengBZBang Zheng
- Anna SchultzeASAnna Schultze
- John TazareJTJohn Tazare
- Viyaasan MahalingasivamVMViyaasan Mahalingasivam
- Peter InglesbyPIPeter Inglesby
- Simon DavySDSimon Davy
- Rebecca SmithRSRebecca Smith
- Amir MehrkarAMAmir Mehrkar
- Christopher BatesCBChristopher Bates
Open Access
- 19 August 2025
- journal article
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 9, 425
Abstract
Background Between December 2021 and June 2023, COVID-19 medicine delivery units (CMDUs) in England offered antiviral medicines and neutralising monoclonal antibodies (paxlovid, sotrovimab, molnupiravir, remdesivir, and casirivimab/imdevimab) to non-hospitalised individuals with COVID-19, identified at high risk of developing severe outcomes. In order to prescribe and supply medicines CMDUs were required to notify NHS England of every prescription via an electronic form. This data was supplied to OpenSAFELY, a secure analytics platform for electronic patient records, as the COVID-19 “Therapeutics” dataset. We aimed to explore the analytic potential of the dataset for research into the use and effectiveness of these therapeutics offered by CMDUs. Methods Working on behalf of NHS England, we assessed the content and data quality of the COVID-19 Therapeutics dataset within OpenSAFELY. We focused on therapeutics provided in outpatient settings by CMDUs. We described for each field the: data format, completeness and summarised its content. Results The COVID-19 Therapeutics dataset contained 18 columns and 58,590 rows of data, for 54,435 distinct patient IDs (92.9%) treated in outpatient settings. The dataset was well-structured, with completeness of almost all fields of 100%. The dataset included details on the specific treatment received, date administered, high-risk group(s) to which the patient belonged and the region in which they were assessed. Conclusion The COVID-19 Therapeutics dataset is well-structured, complete, and is suitable for research. It is linked to other data sources in OpenSAFELY (e.g., primary care), enabling important research on the impact of treatment and health disparities.Keywords
Funding Information
- Wellcome Trust (222097)
- MRC (MR/V015737/1, MC_PC_20030, MC_PC_20059, MC_PC_20058, MC_PC_20051)
- NIHR (COV-LT-0009)
This publication has 8 references indexed in Scilit:
- OpenSAFELY: A platform for analysing electronic health records designed for reproducible researchPharmacoepidemiology and Drug Safety, 2024
- Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk patients during Omicron waves: observational cohort study using the OpenSAFELY platformThe Lancet Regional Health - Europe, 2023
- Comparative effectiveness of sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in patients on kidney replacement therapy: observational study using the OpenSAFELY-UKRR and SRR databasesClinical Kidney Journal, 2023
- Effectiveness of Sotrovimab and Molnupiravir in community settings in England across the Omicron BA.1 and BA.2 sublineages: emulated target trials using the OpenSAFELY platformmedRxiv, 2023
- Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELYBMJ Medicine, 2023
- Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platformBMJ, 2022
- A comprehensive high cost drugs dataset from the NHS in England - An OpenSAFELY-TPP Short Data ReportWellcome Open Research, 2021
- Factors associated with COVID-19-related death using OpenSAFELYNature, 2020